Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Report 2026

The sodium glucose cotransporter 2 (sglt2) inhibitors market size has grown strongly in recent years. It will grow from $10.96 billion in 2025 to $11.87 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to rising type 2 diabetes cases, unmet glycemic control needs, clinical trial success, physician awareness, regulatory approvals.

The sodium glucose cotransporter 2 (sglt2) inhibitors market size is expected to see strong growth in the next few years. It will grow to $16.35 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to cardio-renal benefit recognition, aging diabetic population, expanded reimbursement coverage, new drug launches, emerging market penetration. Major trends in the forecast period include expanded use beyond diabetes, increased combination therapy adoption, growth in heart failure indications, improved safety profiling, wider guideline inclusion.

The rising prevalence of diabetes is expected to drive the growth of the sodium glucose cotransporter 2 (SGLT2) inhibitor market in the coming years. Diabetes is a group of metabolic disorders characterized by elevated blood sugar levels due to defects in insulin secretion, insulin action, or both. The increase in diabetes cases is influenced by factors such as urbanization, stress, environmental pollutants, and limited access to healthcare services. Sodium glucose cotransporter 2 (SGLT2) inhibitors help manage diabetes by lowering blood glucose levels through the prevention of glucose reabsorption in the kidneys, leading to its excretion in urine. These inhibitors also provide cardiovascular and renal benefits, making them an effective option for managing diabetes and its complications. For example, according to the Office for Health Improvement and Disparities (OHID), a UK-based government organization, the prevalence of type 2 diabetes recorded by GPs among adults aged 17 and above in England was 7% in March 2024, up from 6.8% in March 2023. Thus, the rising prevalence of diabetes is fueling the growth of the SGLT2 inhibitor market.

Key players in the SGLT2 inhibitor market are concentrating on developing dual inhibitor therapies to improve patient outcomes and regulate blood sugar levels. Dual inhibitor therapies target two different sodium-glucose cotransporters (SGLT1 and SGLT2) simultaneously to enhance effectiveness in managing conditions such as heart failure and diabetes. For instance, in May 2023, Lexicon Pharmaceuticals Inc., a US-based biopharmaceutical company, received FDA approval for sotagliflozin, a treatment for heart failure. This first-in-class dual inhibitor of SGLT1 and SGLT2 is a once-daily tablet designed to reduce cardiovascular death, heart failure hospitalizations, and urgent heart failure visits in adults with heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. Its benefits include reduced renal glucose and sodium reabsorption, resulting in decreased preload and afterload as well as reduced sympathetic activity.

In October 2024, Viatris Inc., a US-based global healthcare company, entered into an exclusive licensing agreement with Lexicon Pharmaceuticals to commercialize sotagliflozin in all markets outside the U.S. and Europe. The partnership aims to expand access to sotagliflozin, improve treatment options for patients with diabetes, and promote innovation in the global diabetes therapeutics market. Lexicon Pharmaceuticals is a US-based biopharmaceutical company focused on developing novel therapies for metabolic diseases.

Major companies operating in the sodium glucose cotransporter 2 (sglt2) inhibitors market are Johnson & Johnson Inc., Merck & Co Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Astellas Pharma Inc, Sun Pharmaceutical Industries Ltd, Sumitomo Dainippon Pharma Co Ltd, Taisho Pharmaceutical Holdings Co Ltd, Lupin Limited, Glenmark Pharmaceuticals, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Kissei Pharmaceutical Co Ltd, Kotobuki Pharmaceutical Co Ltd, Lexicon Pharmaceuticals Inc, Novartis AG, Takeda Pharmaceutical Company Limited, Hanmi Pharmaceutical Co Ltd, Chong Kun Dang Pharmaceutical Corp, Mitsubishi Tanabe Pharma Corporation.

North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (sglt2) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sodium glucose cotransporter 2 (sglt2) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased costs in the SGLT2 inhibitors market by raising prices for imported active pharmaceutical ingredients and formulation inputs used in branded and generic diabetes drugs. Hospitals and clinics in Asia-Pacific and Europe that rely on global pharmaceutical supply chains are most affected, resulting in higher drug prices. These cost pressures can impact patient access to newer SGLT2 inhibitor therapies. However, tariffs are encouraging domestic API production and generic drug manufacturing, supporting long-term affordability in the SGLT2 inhibitors market.

The sodium glucose cotransporter 2 (sglt2) inhibitors market research report is one of a series of new reports that provides sodium glucose cotransporter 2 (sglt2) inhibitors market statistics, including sodium glucose cotransporter 2 (sglt2) inhibitors industry global market size, regional shares, competitors with a sodium glucose cotransporter 2 (sglt2) inhibitors market share, detailed sodium glucose cotransporter 2 (sglt2) inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the sodium glucose cotransporter 2 (sglt2) inhibitors industry. This sodium glucose cotransporter 2 (sglt2) inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Sodium glucose cotransporter 2 (SGLT2) inhibitors are a group of drugs used to manage type 2 diabetes by inhibiting the SGLT2 protein in the kidneys, which prevents glucose reabsorption and promotes its excretion through urine. This mechanism helps reduce blood glucose levels and may also aid in weight loss and lower blood pressure. They offer additional cardiovascular and renal benefits, making them important in the management of diabetic complications.

The primary types of sodium glucose cotransporter 2 (SGLT2) inhibitors include Invokana, Jardiance, Farxiga (or Forxiga), and Suglat. Invokana is a prescription medication used to lower blood sugar levels in adults with type 2 diabetes. These drugs are generally administered orally and are used by end users such as hospitals, clinics, and homecare settings.

The sodium glucose cotransporter 2 (SGLT2) inhibitors market consists of sales of luseogliflozin, remogliflozin, tofogliflozin and sergliflozin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.